Parkinsonism & Related Disorders

Article	Citations
Altered glymphatic system in idiopathic normal pressure hydrocephalus	110
Linear predictive coding distinguishes spectral EEG features of Parkinson's disease	86
Diffusion along perivascular spaces reveals evidence supportive of glymphatic function impairment in Parkinson disease	78
Increased microglial activation in patients with Parkinson disease using [18F]-DPA714 TSPO PET imaging	71
Altered gut microbiota in Parkinson's disease patients/healthy spouses and its association with clinical features	70
Gut microbiome in Parkinson's disease: New insights from meta-analysis	68
Unmet needs in Parkinson disease: Motor and non-motor	67
The changes of exercise pattern and clinical symptoms in patients with Parkinson's disease in the era of COVID-19 pandemic	49
Parkinson's disease may worsen outcomes from coronavirus disease 2019 (COVID-19) pneumonia in hospitalized patients: A systematic review, meta-analysis, and meta-regression	48
Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study	47
Exosomal miRNA as peripheral biomarkers in Parkinson's disease and progressive supranuclear palsy: A pilot study	46
COVID-19 in Parkinson's disease: Report on prevalence and outcome	45
Cerebral small vessel disease may worsen motor function, cognition, and mood in Parkinson's disease	42
Probiotics for constipation and gut microbiota in Parkinson's disease	41
Serum NFL levels predict progression of motor impairment and reduction in putamen dopamine transporter binding ratios in de novo Parkinson's disease: An 8-year longitudinal study	39
Digital health technology for non-motor symptoms in people with Parkinson's disease: Futile or future?	39
Tau and MAPT genetics in tauopathies and synucleinopathies	37
Hierarchical cluster analysis of multimodal imaging data identifies brain atrophy and cognitive patterns in Parkinson’s disease	35
How do adenosine A2A receptors regulate motor function?	35
Effects of cerebellar transcranial magnetic stimulation on ataxias: A randomized trial	34
The challenge of developing adenosine A2A antagonists for Parkinson disease: Istradefylline, preladenant, and tozadenant	34
Plasma NfL, clinical subtypes and motor progression in Parkinson's disease	34
Excessive daytime sleepiness in Parkinson's disease: A systematic review and meta-analysis	34
Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation in primary patient-derived macrophages in Gaucher disease and Parkinsonism	33
Diagnostic value of α-synuclein seeding amplification assays in α-synucleinopathies: A systematic review and meta-analysis	33

The use of wearable/portable digital sensors in Huntington's disease: A systematic review	32
Impact of home confinement during COVID-19 pandemic on Parkinson's disease	32
Prediabetes, type 2 diabetes mellitus and risk of Parkinson’s disease: A population-based cohort study	32
Parkinson's disease and skin	31
Predicting Parkinson's disease using gradient boosting decision tree models with electroencephalography signals	31
Prevalence of ten LRRK2 variants in Parkinson's disease: A comprehensive review	31
High-frequency repetitive transcranial magnetic stimulation over the primary motor cortex relieves musculoskeletal pain in patients with Parkinson's disease: A randomized controlled trial	30
ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: A randomized, placebo-controlled phase 2 study	30
Validation and clinical value of the MANAGE-PD tool: A clinician-reported tool to identify Parkinson's disease patients inadequately controlled on oral medications	29
Use of machine learning method on automatic classification of motor subtype of Parkinson's disease based on multilevel indices of rs-fMRI	29
Dysphagia in multiple system atrophy consensus statement on diagnosis, prognosis and treatment	29
Features of “ET plus” correlate with age and tremor duration: “ET plus” may be a disease stage rather than a subtype of essential tremor	28
Art therapy for Parkinson's disease	27
Plasma and serum alpha-synuclein as a biomarker in Parkinson's disease: A meta-analysis	26
Parkinson's disease advanced therapies - A systematic review: More unanswered questions than guidance	26
Comparison of 123I-MIBG scintigraphy and phosphorylated α-synuclein skin deposits in synucleinopathies	26
Movement disorders induced by psychiatric drugs that do not block dopamine receptors	25
The inconsistency and instability of Parkinson's disease motor subtypes	25
Closed-loop programming using external responses for deep brain stimulation in Parkinson's disease	25
Subjective cognitive Complaints in early Parkinson's disease patients with normal cognition are associated with affective symptoms	24
Can adenosine A2A receptor antagonists be used to treat cognitive impairment, depression or excessive sleepiness in Parkinson's disease?	24
Association of PSP phenotypes with survival: A brain-bank study	23
Cerebello-basal ganglia connectivity fingerprints related to motor/cognitive performance in Parkinson's disease	23
Peripheral insulin and amylin levels in Parkinson's disease	23
Long-term effect of bilateral STN-DBS on non-motor symptoms in Parkinson's disease: A four-year observational, prospective study	23
The evolution of parkinsonism in primary progressive apraxia of speech: A 6-year longitudinal study	23
Uptake of telehealth in Parkinson's disease clinical care and research during the COVID-19 pandemic	23
Prevalence and clinical associations of tau in Lewy body dementias: A systematic review and meta-analysis	23
Diagnostic criteria for blepharospasm: A multicenter international study	23
Plasma neurofilament light in Huntington's disease: A marker for disease onset, but not symptom progression	22
Are there morphological differences between Parkinson's disease-dementia and dementia with Lewy bodies?	22
Functional movement disorder comorbidity in Parkinson's disease: Unraveling the web	22
Classification and staging of Parkinson's disease using video-based eye tracking	22
Serum neurofilament is associated with motor function, cognitive decline and subclinical cardiac damage in advanced Parkinson's disease (MARK-PD)	22
The diagnostic value of clinical neurophysiology in hyperkinetic movement disorders: A systematic review	22
A French survey on the lockdown consequences of COVID-19 pandemic in Parkinson's disease. The ERCOPARK study	22
Do caffeine and more selective adenosine A2A receptor antagonists protect against dopaminergic neurodegeneration in Parkinson's disease?	21
Cognitive impairment in Parkinson's disease is associated with Default Mode Network subsystem connectivity and cerebrospinal fluid Aβ	21
Social cognitive impairment in early Parkinson's disease: A novel “mild impairment”?	21
A pilot to assess target engagement of terazosin in Parkinson's disease	21
Sex differences in dementia with Lewy bodies: Focused review of available evidence and future directions	20
Perivascular space in Parkinson's disease: Association with CSF amyloid/tau and cognitive decline	20
Dual-task clinical and functional MRI correlates in Parkinson's disease with postural instability and gait disorders	20
Necessity and feasibility of remote tele-programming of deep brain stimulation systems in Parkinson's disease	20
Can AI make people happy? The effect of AI-based chatbot on smile and speech in Parkinson's disease	20
Combined CSF α-SYN RT-QuIC, CSF NFL and midbrain-pons planimetry in degenerative parkinsonisms: From bedside to bench, and back again	20
A validated measure of rigidity in Parkinson's disease using alternating finger tapping on an engineered keyboard	19
Prefrontal network dysfunctions in rapid eye movement sleep behavior disorder	19
Geospatial analysis of individual-based Parkinson's disease data supports a link with air pollution: A case-control study	19
α-Synuclein seed amplification assay as a diagnostic tool for parkinsonian disorders	19

Mind the gap: Inequalities in mental health care and lack of social support in Parkinson disease	19
Anxiety in Parkinson's disease is associated with changes in the brain fear circuit	19
The commercial genetic testing landscape for Parkinson's disease	19
Voice characteristics from isolated rapid eye movement sleep behavior disorder to early Parkinson's disease	19
Parkinsonism in children: Clinical classification and etiological spectrum	19
Telemedicine and Deep brain stimulation - Current practices and recommendations	19
Automated assessment of the substantia nigra on susceptibility map-weighted imaging using deep convolutional neural networks for diagnosis of Idiopathic Parkinson's disease	19
Retinal thickness and microvascular pathway in Idiopathic Rapid eye movement sleep behaviour disorder and Parkinson's disease	19
Consistent skin α-synuclein positivity in REM sleep behavior disorder – A two center two-to-four-year follow-up study	18
Digital phenotyping in Parkinson's disease: Empowering neurologists for measurement-based care	18
IRF2BPL mutation causes nigrostriatal degeneration presenting with dystonia, spasticity and keratoconus	18
A new alpha-synuclein missense variant (Thr72Met) in two Turkish families with Parkinson's disease	18
A randomised double-blind controlled study of Deep Brain Stimulation for dystonia in STN or GPi – A long term follow-up after up to 15 years	18
Objective measurement of limb bradykinesia using a marker-less tracking algorithm with 2D-video in PD patients	18
Multidisciplinary inpatient rehabilitation for Functional Movement Disorders: A prospective study with long term follow up	18
Glymphatic function assessment in Parkinson's disease using diffusion tensor image analysis along the perivascular space	18
Toll-like receptor 4 deficiency facilitates α-synuclein propagation and neurodegeneration in a mouse model of prodromal Parkinson's disease	17
Low-frequency oscillation suppression in dystonia: Implications for adaptive deep brain stimulation	17
Relating Parkinson freezing and balance domains: A structural equation modeling approach	17
Normal cognition in Parkinson's disease may involve hippocampal cholinergic compensation: An exploratory PET imaging study with [18F]-FEOBV	17
In vivo cholinergic basal forebrain degeneration and cognition in Parkinson's disease: Imaging results from the COPPADIS study	17
Neurogenic orthostatic hypotension in early stage Parkinson's disease: New insights from the first 105 patients of the BoProPark study	17
WARS2 mutations cause dopa-responsive early-onset parkinsonism and progressive myoclonus ataxia	17
Impaired metabolic brain networks associated with neurotransmission systems in the α-synuclein spectrum	17
Biofluid markers of blood-brain barrier disruption and neurodegeneration in Lewy body spectrum diseases: A systematic review and meta-analysis	16
Quantitative mobility measures complement the MDS-UPDRS for characterization of Parkinson's disease heterogeneity	16
The faecal metabolome and mycobiome in Parkinson's disease	16
Clinically relevant copy-number variants in exome sequencing data of patients with dystonia	16
Foslevodopa/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to levodopa-carbidopa intestinal gel delivered to the jejunum	16
GNAO1-related movement disorder: An update on phenomenology, clinical course, and response to treatments	16
Cognitive impairment in Parkinson's disease: Associations between subjective and objective cognitive decline in a large longitudinal study	16
Should we start integrating genetic data in decision-making on device-aided therapies in Parkinson disease? A point of view	16
Bilateral pallidal stimulation improves cervical dystonia for more than a decade	16
Cortical atrophy distinguishes idiopathic normal-pressure hydrocephalus from progressive supranuclear palsy: A machine learning approach	16
A trial of buspirone for anxiety in Parkinson's disease: Safety and tolerability	16
Clinical features of autopsy-confirmed multiple system atrophy in the Mayo Clinic Florida brain bank	16
Scientific impact of movement disorders research from Southeast Asia: A bibliometric analysis	16
Cortical cholinergic dysfunction correlates with microglial activation in the substantia innominata in REM sleep behavior disorder	16
Effect of deep brain stimulation on caregivers of patients with Parkinson's disease: A systematic review	15
Exploring the clinical meaningfulness of the Scale for the Assessment and Rating of Ataxia: A comparison of patient and physician perspectives at the item level	15
Diagnostic accuracy of MR planimetry in clinically unclassifiable parkinsonism	15
Drooling rating scales in Parkinson's disease: A systematic review	15
Dentate nucleus stimulation for essential tremor	15
Ataxia and tolerance after thalamic deep brain stimulation for essential tremor	15
Association of lipid levels with motor and cognitive function and decline in advanced Parkinson's disease in the Mark-PD study	15
Dissociable contribution of plasma NfL and p-tau181 to cognitive impairment in Parkinson's disease	15
Apolipoprotein E ε4 genotype and risk of freezing of gait in Parkinson's disease	15
Patterns and predictors of referrals to allied health services for individuals with Parkinson's disease: A Parkinson's foundation (PF) QII study	15
Determining an efficient deep brain stimulation target in essential tremor - Cohort study and review of the literature	15
Constipation distinguishes different clinical-biochemical patterns in de novo Parkinson's disease	15
Machine learning trained with quantitative susceptibility mapping to detect mild cognitive impairment in Parkinson's disease	15
Cerebrospinal fluid and plasma distribution of anti-α-synuclein IgMs and IgGs in multiple system atrophy and Parkinson's disease	15
Clinical manifestations of Parkinson's disease harboring VPS35 retromer complex component p.D620N with long-term follow-up	15
Clinical perception and management of Parkinson's disease during the COVID-19 pandemic: A Canadian experience	15
Paired inhibitory stimulation and gait training modulates supplemental motor area connectivity in freezing of gait	15
A 12-month, dose-level blinded safety and efficacy study of levodopa inhalation powder (CVT-301, Inbrija) in patients with Parkinson's disease	15
Spinocerebellar ataxias in Asia: Prevalence, phenotypes and management	14
The Cortical Basal ganglia Functional Scale (CBFS): Development and preliminary validation	14
Clarification of undiagnosed ataxia using whole-exome sequencing with clinical implications	14
Clinical-Instrumental patterns of neurodegeneration in Essential Tremor: A data-driven approach	14
Open-label titration of apomorphine sublingual film in patients with Parkinson's disease and “OFF” episodes	14
Neuromelanin-sensitive magnetic resonance imaging in disease differentiation for parkinsonism or neurodegenerative disease affecting the basal ganglia	14
Relationship between risk and protective factors and clinical features of Parkinson's disease	14
Effect of eight-week online cognitive training in Parkinson's disease: A double-blind, randomized, controlled trial	14
Motor and non-motor subtypes of cervical dystonia	13
Isolated parkinsonism is an atypical presentation of GRN and C9orf72 gene mutations	13
Analysis of nationwide multimodal complex treatment and drug pump therapy in Parkinson's disease in times of COVID-19 pandemic in Germany	13
PINK1 p.Leu347Pro mutations in Malays: Prevalence and illustrative cases	13
Fatigue in hypokinetic, hyperkinetic, and functional movement disorders	13
Expanding sexual and gender minority research in movement disorders: More than awareness and acceptance	13
Multimodal assessment of nigrosomal degeneration in Parkinson's disease	13
Progressive microstructural alterations in subcortical nuclei in Parkinson's disease: A diffusion magnetic resonance imaging study	13
High intensity aerobic exercise improves bimanual coordination of grasping forces in Parkinson's disease	13
Noninvasive neuroimaging provides evidence for deterioration of the glymphatic system in Parkinson's disease relative to essential tremor	13
The amplitude of low-frequency fluctuation predicts levodopa treatment response in patients with Parkinson's disease	13
Deep brain stimulation fine-tuning in Parkinson's disease: Short pulse width effect on speech	13
Patterns of diffusion kurtosis changes in Parkinson's disease subtypes	13
The cerebellum in idiopathic cervical dystonia: A specific pattern of structural abnormalities?	13
Automated brainstem volumetry can aid in the diagnostics of parkinsonian disorders	13
α and θ oscillations in the subthalamic nucleus are potential biomarkers for Parkinson's disease with depressive symptoms	13

No enhanced (p-) α-synuclein deposition in gastrointestinal tissue of Parkinson's disease patients	13
Clinical patterns of gait freezing in Parkinson's disease and their response to interventions: An observer-blinded study	13
Dystonia as a prominent presenting feature in developmental and epileptic encephalopathies: A case series	13
Predicting Parkinson's disease trajectory using clinical and neuroimaging baseline measures	13
Altered gut microbiota in Parkinson's disease patients with motor complications	13
Genetic variants in levodopa-induced dyskinesia (LID): A systematic review and meta-analysis	13
Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patients	13
Predictors of fatigue severity in early, de novo Parkinson disease patients: A 1-year longitudinal study	13
Lesions of the cerebello-thalamic tract rather than the ventral intermediate nucleus determine the outcome of focused ultrasound therapy in essential tremor: A 3T and 7T MRI–study	12
Increased prevalence of Parkinson's disease in soils with high arsenic levels	12
Can adenosine A2A receptor antagonists modify motor behavior and dyskinesia in experimental models of Parkinson's disease?	12
Longitudinal evaluation of patients with isolated head tremor	12
Cerebrospinal fluid biomarker profiling in corticobasal degeneration: Application of the AT(N) and other classification systems	12
The neurological and neuropsychiatric spectrum of adults with late-treated phenylketonuria	12
Natural speech markers of Alzheimer's disease co-pathology in Lewy body dementias	12
Retinal microvascular impairment in Parkinson's disease with cognitive dysfunction	12
Structural and functional brain abnormalities in idiopathic cervical dystonia: A multimodal meta-analysis	12
Cortical microstructural correlates of plasma neurofilament light chain in Huntington's disease	12
Multimodal dopamine transporter (DAT) imaging and magnetic resonance imaging (MRI) to characterise early Parkinson's disease	12
‘Anxious fluctuators’ a subgroup of Parkinson's disease with high anxiety and problematic on-off fluctuations	12
The association of comorbidity with Parkinson's disease-related hospitalizations	12
Biofluids profile of α-Klotho in patients with Parkinson's disease	12
Beta power and movement-related beta modulation as hallmarks of energy for plasticity induction: Implications for Parkinson's disease	12
How specific are non-motor symptoms in the prodrome of Parkinson's disease compared to other movement disorders?	12
White matter hyperintensities mediate the impact of amyloid ß on future freezing of gait in Parkinson's disease	12
Rest tremor correlates with reduced contralateral striatal dopamine transporter binding in Parkinson's disease	12
Neuroimaging outcomes associated with mild cognitive impairment subtypes in Parkinson's disease: A systematic review	12
A Bayesian approach to Essential Tremor plus: A preliminary analysis of the TITAN cohort	12
Dynamic functional connectivity impairments in idiopathic rapid eye movement sleep behavior disorder	12
Soluble LAG-3 and Toll-interacting protein: Novel upstream neuro-inflammatory markers in Parkinson's disease	11
Renin-angiotensin system blockers affect cognitive decline in Parkinson's disease: The PPMI dataset	11
VPS13C-associated Parkinson's disease: Two novel cases and review of the literature	11
Seeking progress in disease modification in Parkinson disease	11
Serum uric acid level as a putative biomarker in Parkinson's disease patients carrying GBA1 mutations: 2-Year data from the PPMI study	11
Association between probable REM sleep behavior disorder and increased dermal alpha-synuclein deposition in Parkinson's disease	11
Homozygosity mapping and next generation sequencing for the genetic diagnosis of hereditary ataxia and spastic paraplegia in consanguineous families	11
Nucleus basalis of Meynert predicts cognition after deep brain stimulation in Parkinson's disease	11
Initial center of pressure position prior to anticipatory postural adjustments during gait initiation in people with Parkinson's disease with freezing of gait	11
Physical activity intensity is associated with cognition and functional connectivity in Parkinson's disease	11
Urine levels of the polyglutamine ataxin-3 protein are elevated in patients with spinocerebellar ataxia type 3	11
The “round the houses” sign and “zig-zag” sign in progressive supranuclear palsy and other conditions	11
Point of view: Wearable systems for at-home monitoring of motor complications in Parkinson's disease should deliver clinically actionable information	11
Electroretinography reveals retinal dysfunction in Parkinson's disease despite normal high-resolution optical coherence tomography findings	11
Postural abnormalities in Asian and Caucasian Parkinson's disease patients: A multicenter study	11
Short-term efficacy of repetitive transcranial magnetic stimulation in SCA3: A prospective, randomized, double-blind, sham-controlled study	11
Data from ENROLL-HD: Is the prevalence of juvenile and pediatric Huntington's disease overestimated?	11
Weight loss and weight gain in Parkinson disease	11
Diagnosis of Parkinson's disease from hand drawing utilizing hybrid models	11
Exome-wide rare variant analysis in familial essential tremor	11
The global pandemic has permanently changed the state of practice for pre-DBS neuropsychological evaluations	11
Subcortical microstructural diffusion changes correlate with gait impairment in Parkinson's disease	11
Early factors for predicting discontinuation to subcutaneous Apomorphine infusion in Parkinson's disease: A prospective analysis of the Thai Apomorphine Registry	11
Movement disorders in systemic autoimmune diseases: Clinical spectrum, ancillary investigations, pathophysiological considerations	11
Sleep disturbances by disease type and stage in Huntington's disease	11
Accuracy and precision of wrist-worn actigraphy for measuring steps taken during over-ground and treadmill walking in adults with Parkinson's disease	11
Mutation screening of VPS16 gene in patients with isolated dystonia	11
Staying hidden: The burden of stigma in PD	11
Cognitive impairment in spinocerebellar ataxia type 12	11
Anterior lead location predicts verbal fluency decline following STN-DBS in Parkinson's disease	11
Unraveling Parkinson's disease heterogeneity using subtypes based on multimodal data	11
Correlations between retinal nerve fiber layer thickness and cognitive progression in Parkinson's disease: A longitudinal study	11
Exploring three levels of interoception in people with functional motor disorders	11
Hippocampal and insula volume in mild cognitive impairment with Lewy bodies	11
Deep brain stimulation for atypical parkinsonism: A systematic review on efficacy and safety	11
Genetic overlap between dystonia and other neurologic disorders: A study of 1,100 exomes	11
Non-motor effects of deep brain stimulation in Parkinson's disease motor subtypes	10
Spread of segmental/multifocal idiopathic adult-onset dystonia to a third body site	10
Changes in prefrontal cortical activity and turning in response to dopaminergic and cholinergic therapy in Parkinson's disease: A randomized cross-over trial	10
IN-HOME-PD: The effects of longitudinal telehealth-enhanced interdisciplinary home visits on care and quality of life for homebound individuals with Parkinson's disease	10
Associations between prognostic index scores and plasma neurofilament light in Huntington's disease	10
Parkinson’s disease related mortality: Long-term trends and impact of COVID-19 pandemic waves	10
Idiopathic rapid eye movement sleep behavior disorder in Japan: An observational study	10
Enhanced arm swing improves Parkinsonian gait with EEG power modulations resembling healthy gait	10
The actual use of directional steering and shorter pulse width in selected patients undergoing deep brain stimulation	10
Neural correlates of attentional deficits in Parkinson's disease patients with mild cognitive impairment	10
Prevalence and associated factors of malnutrition in patients with Parkinson's disease using CONUT and GNRI	10
Neural networks associated with quality of life in patients with Parkinson's disease	10
Association between statin use and Parkinson's disease in Korean patients with hyperlipidemia	10
Articulatory network reorganization in Parkinson's disease as assessed by multimodal MRI and acoustic measures	10
Differential diagnosis of tremor syndromes using MRI relaxometry	10
Movement disorders in ADAR1 disease: Insights from a comprehensive cohort	10
A randomized clinical trial of burst vs. spaced physical therapy for Parkinsons disease	10
A multimodal approach using TMS and EEG reveals neurophysiological changes in Parkinson's disease	10
Pre-diagnostic presentations of Multiple System Atrophy case control study in a primary care dataset	10
Plasma acyl-carnitines, bilirubin, tyramine and tetrahydro-21-deoxycortisol in Parkinson's disease and essential tremor. A case control biomarker study	10
Parkinson's disease patients may have higher rates of Covid-19 mortality in Iran	10
FXTAS presents with upregulation of the cytokines IL12 and TNFα	10
Action observation improves sit-to-walk in patients with Parkinson's disease and freezing of gait. Biomechanical analysis of performance	10
People with Parkinson's report increased impulse control behaviours during the COVID-19 UK lockdown	9
Cortical hypometabolism associated with cognitive impairment of multiple system atrophy	9
Preformed fibrils generated from mouse alpha-synuclein produce more inclusion pathology in rats than fibrils generated from rat alpha-synuclein	9
Associations between white matter hyperintensities, striatal dopamine loss, and cognition in drug-naïve Parkinson's disease	9
The relationship between plasma biomarkers and amyloid PET in dementia with Lewy bodies	9
Levodopa responsive-generalized dystonic spells and moaning in DNAJC6 related Juvenile Parkinson’s disease	9
Establishing a framework for quality of inpatient care for Parkinson's disease: A study on inpatient medication administration	9